Ryvu Therapeutics

Edison Investment Research is terminating coverage on Ryvu Therapeutics. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Equities

Equities by Sector

Sectors

Thematics

Latest

Healthcare-focused trusts: A sector on the mend

MediaWatch – One step forward, two steps back

ConsumerWatch – Don’t look down

Audiovisual

Latest

Recce Pharmaceuticals – executive interview

VEON – executive interview with CFO Joop Brakenhoff

VEON – executive interview with CEO Kaan Terzioğlu

About Edison

About Edison

Careers

Ryvu Therapeutics (WSE: RVU)

Latest Insights

Ryvu Therapeutics — Rebalancing R&D pipeline towards clinical stage

Ryvu Therapeutics — Diversified pipeline ensures continued newsflow

Ryvu Therapeutics — Successful Phase I with SEL24/MEN1703

Ryvu Therapeutics — First ever clinical data from lead assets in 2020

Sector

Financials

Research

Selvita — New funds enable expanded R&D programme

Selvita — Phase I/II with SEL24 to continue

Selvita — Progress across pipeline; Services sales up 53%

Selvita — New 2017-2021 strategy to boost R&D

Selvita — Clinical hold on SEL24

Selvita — Menarini Group in-licensed SEL24

Selvita — SEL24 enters Phase I/II

Selvita — Update 22 November 2016

Selvita — Update 14 October 2016

Selvita — Update 22 August 2016

Selvita — Update 17 June 2016

Selvita — Update 25 April 2016

Selvita — Update 8 December 2015

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time